ライフサイエンスコーパス: liposomal

1 The liposomal 5(6)-carboxy-DCFH2 can be targeted to other ti

2 Liposomal accumulation in tumors and organs was followed

3 tumor development in patients, showed higher liposomal accumulation than slow-growing xenografts.

4 omote a depot after administration, with the liposomal adjuvant and the antigen both being retained a

5 Furthermore, a liposomal adjuvant with QS21 and a TLR4 agonist (GLA-LSQ

6 accine Ag doses with a novel potent cationic liposomal adjuvant, cationic adjuvant formulation 09, co

7 Liposomal ALD (L-ALD) has been suggested as a suitable a

8 wn in both in vitro and in vivo studies that liposomal alendronate (L-ALD) can sensitise cancer cells

9 Importantly however, liposomal alendronic acid proved markedly superior compa

10 By contrast, the maximum tolerated dose of liposomal alendronic acid was 150-fold higher, rendering

11 njected into the peritoneal cavity, free and liposomal alendronic acid were both highly effective as

12 nfused gammadelta T cells are targeted using liposomal alendronic acid.

13 , we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-ref

14 ay [BID]), voriconazole (10 mg/kg p.o. BID), liposomal amphotericin B (10 mg/kg intraperitoneally [i.

15 %), caspofungin (24%), voriconazole (8%), or liposomal amphotericin B (5%).

16 reated with 30 mg/kg body weight intravenous liposomal amphotericin B (AmBisome) divided as 6 equal d

17 teria, reporting comparisons of fluconazole, liposomal amphotericin B (L-AmB), itraconazole, micafung

18 The optimal dosage of liposomal amphotericin B (LAmB) alone or in combination

19 tolerability of high-dose weekly (10 mg/kg) liposomal amphotericin B (LamB) for antifungal prophylax

20 -derivatized-dendrimer (PDD), complexed with liposomal amphotericin B (LAmB) in an L. major mouse mod

21 We have evaluated liposomal amphotericin B in 20 patients with DL in an op

22 Liposomal amphotericin B is an effective therapy for DL,

23 s with previous severe infusion reactions to liposomal amphotericin B is unclear.

24 Although liposomal amphotericin B was considered well tolerated,

25 Liposomal amphotericin B was started within a median of

26 fungal agents (voriconazole, with or without liposomal amphotericin B), and 24 required surgical debr

27 phigus foliaceus died despite treatment with liposomal amphotericin B, 3 mg/kg/d, and a young girl wi

28 The patient was treated initially with liposomal amphotericin B, 430 mg daily, but changed to v

29 antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be mu

30 center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant

31 hen prospectively screened twice a week, and liposomal amphotericin-B therapy initiated based on a po

32 B) for protein detection, which integrates a liposomal amplifier and sandwich immunoassay format with

33 Liposomal and cellular transport activity of the squaram

34 ficacy in patients was not different between liposomal and conventional chemotherapy as assessed by o

35 Novel carriers include liposomal and polymeric nanoparticles, wafers, microchip

36 tients with T1 disease treated with cART and liposomal anthracycline chemotherapy, 5-year overall sur

37 ith advanced-stage (T1) KS receive cART plus liposomal anthracycline chemotherapy.

38 Using a targeted liposomal approach, we were able to increase AZ7379 avai

39 findings have translational implications for liposomal approaches as well as for Apo2L/TRAIL and othe

40 We have demonstrated that a liposomal array of well-ordered trimers enhances B cell

41 Directly delivering extrinsic liposomal ATP promoted the drug release from the fusogen

42 Liposomal batches were characterized and compared for th

43 The osmotic pressure across the liposomal bilayer was varied to induce shape deformation

44 ic vaccines, melanoma-associated antigen-A3, liposomal BLP-25, TG4010, and recombinant human epiderma

45 These liposomal bortezomib nanoparticles demonstrated signific

46 Our strategy yielded stable liposomal bortezomib nanoparticles with a narrow size ra

47 n this study, we describe the development of liposomal bortezomib nanoparticles, which was accomplish

48 Taken together, these data support that liposomal bortezomib, as a single agent, eradicates Mll(

49 gery compared with those who did not receive liposomal bupivacaine (mean [SD] age, 64.9 [8.4] years;

50 Among 199 patients, those who received liposomal bupivacaine after primary TKA (mean [SD] age,

51 Drug utilization evaluation of liposomal bupivacaine for local infiltration in TKA.

52 3, 2014-March 2, 2015) the implementation of liposomal bupivacaine for local infiltration in TKA.

53 [3.0-7.5]; P = .001), patients who received liposomal bupivacaine had greater median (interquartile

54 Liposomal bupivacaine is a novel extended-duration anest

55 Athough liposomal bupivacaine is widely used, it is unknown if t

56 ractice: the effect of local infiltration of liposomal bupivacaine on perioperative outcomes in patie

57 Local infiltration of liposomal bupivacaine reduces use of opioids in the firs

58 nesthesia care unit among those who received liposomal bupivacaine vs those who did not (4 vs 20; P =

59 it were improved among patients who received liposomal bupivacaine vs those who did not (4.0 [0.0-6.6

60 o pain was improved among those who received liposomal bupivacaine vs those who did not (44 vs 19; P

61 was also reduced among patients who received liposomal bupivacaine vs those who did not (49 vs 91; P

62 after surgery than those who did not receive liposomal bupivacaine.

63 Here, we used liposomal CA4P, an antivascular drug, to demonstrate tha

64 Finally, liposomal carfilzomib demonstrated enhanced synergy in c

65 In vivo, liposomal carfilzomib demonstrated significant tumor gro

66 tudy establishes the successful synthesis of liposomal carfilzomib nanoparticles that demonstrates im

67 Here, we report the engineering of liposomal carfilzomib nanoparticles to overcome these pr

68 Liposomal carfilzomib nanoparticles were efficiently tak

69 nticity of the strong CD8(+) T-cell inducing liposomal cationic adjuvant formulation 09 (CAF09), whic

70 argeting AnxA2 (shAnxA2) was formulated in a liposomal (cationic ligand-guided, CLG) carrier and char

71 clude that simple analytical measurements of liposomal changes in lipid packaging, permeability, and

72 The efficient delivery of liposomal chemotherapeutics relies, however, on the enha

73 Liposomal chemotherapy offers several advantages over co

74 al schistosomiasis with macrophage-depleting liposomal clodronate (LC) to define how macrophages medi

75 rophages in the bladder by administration of liposomal clodronate led to higher UPEC burdens.

76 We found that liposomal clodronate pretreatment of C57BL/6 mice permit

77 ctomy or depletion of splenic macrophages by liposomal clodronate protects against PIFA-induced chemo

78 Macrophage depletion by liposomal clodronate resulted in a reversal of the benef

79 icroglia from the fetal cerebral cortex with liposomal clodronate significantly increased the number

80 Use of liposomal clodronate to deplete resident AMs (rAMs) resu

81 Mice were treated with liposomal clodronate to investigate the effect of macrop

82 by depletion of monocytes or macrophages by liposomal clodronate treatment or genetic deficiency of

83 anced by pre-treatment of the recipient with liposomal clodronate, a macrophage depleting agent, with

84 By depleting macrophages using liposomal clodronate, we found that alveolarization defe

85 At day 30, liposomal clodronate-mediated macrophage depletion reduc

86 Liposomal clodronate-mediated macrophage depletion signi

87 trolled by external signals as well as inter-liposomal communication without crosstalk.

88 Delivery of the liposomal constructs and cell destruction correlated wel

89 ercalates into the phospholipid layer of the liposomal core via hydrophobic interactions.

90 These particles consist of 30 nm liposomal cores, composed of an FDA-approved 1,2-dioleoy

91 Future clinical trials should assess liposomal cyclosporine in larger study populations.

92 rgeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therap

93 s of rituximab and four doses of intrathecal liposomal cytarabine.

94 inical trials directly comparing efficacy of liposomal cytotoxic chemotherapy versus their equivalent

95 Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen, Craigavon

96 ty, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher

97 d the toxicity of doxorubicin, non-pegylated liposomal-delivered doxorubicin, and epirubicin in HL-1

98 geted liposomal doxorubicin, which increased liposomal delivery and toxicity to lung cancer cells in

99 e model and predict API suitability for nano-liposomal delivery by fixing the main experimental condi

100 ron neutron capture therapy (BNCT) following liposomal delivery of a (10)B-enriched polyhedral borane

101 IG-I/MAVS pathway is stimulated, such as via liposomal delivery of poly(I:C).

102 e present study, we developed an Ab-targeted liposomal delivery strategy using a clinically relevant

103 We have developed a liposomal delivery system for a prodrug of vinblastine (

104 The use of liposomal delivery systems for the treatment of cancer h

105 Liposomal delivery systems offer tools to modify pharmac

106 develop new quantitative strategies to track liposomal delivery systems to improve the therapeutic in

107 preventing the development of fibrosis after liposomal depletion of circulating monocytes.

108 The lower degree of lipid oxidation in liposomal dispersions containing amino acids might be at

109 Marine phospholipids liposomal dispersions were prepared from two authentic s

110 evaluated the influence of the EPR effect on liposomal distribution in vivo by injection of pegylated

111 igned a fibronectin-targeting CREKA-modified liposomal doxorubicin (CREKA-Lipo-Dox) for the therapy o

112 e impact of three weekly sessions of FUS and liposomal doxorubicin (DOX) in 9L rat glioma tumors.

113 herapeutic outcomes than clinically approved liposomal doxorubicin (Doxil) in HER2-overexpressing BT4

114 tandard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt to provide

115 es were based on the clinical formulation of liposomal doxorubicin (i.e. DOXIL(R)) and were loaded wi

116 Studies have shown that liposomal doxorubicin (Lipo-DOX), a chemotherapy agent w

117 valuated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD alone.

118 fficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.

119 Since pegylated liposomal doxorubicin (PLD) was the most prevalent formu

120 valuated rituximab 375 mg/m(2) combined with liposomal doxorubicin 20 mg/m(2) (R-Dox) every 3 weeks i

121 r photodynamic damage, resulting in enhanced liposomal doxorubicin accumulation in tumors.

122 amycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with a

123 ines of conventional chemotherapy (pegylated liposomal doxorubicin and docetaxel) was treated with le

124 in tumors treated with temperature-sensitive liposomal doxorubicin and ultrasound hyperthermia.

125 or reduced cardiac toxicity of non-pegylated-liposomal doxorubicin characterized by attenuation of RO

126 free doxorubicin and was superior to that of liposomal doxorubicin formulations.

127 his FUS technique to enhance the delivery of liposomal doxorubicin have a pronounced therapeutic effe

128 oxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to fre

129 sus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinum-resistan

130 In the healthy mouse, non-pegylated liposomal doxorubicin showed a minimal and non-significa

131 technique is able to identify both free and liposomal doxorubicin throughout the spheroid after just

132 Thermosensitive liposomal doxorubicin was administered systemically duri

133 ermined amount of the chemotherapeutic drug (liposomal doxorubicin) into the brain.

134 acizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE)

135 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DA

136 Liposomal doxorubicin, bevacizumab, and the mTOR inhibit

137 g or efficacy for H2009.1 tetrameric peptide liposomal doxorubicin, compared to control peptide and n

138 Spheroids were dosed with liposomal doxorubicin, free doxorubicin, or media contro

139 vestigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or topotecan),

140 lphavbeta6-specific H2009.1 peptide targeted liposomal doxorubicin, which increased liposomal deliver

141 2) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (1

142 ding an additional anti-tumor adjuvant agent liposomal doxorubicin.

143 eekly doses of gemcitabine, vinorelbine, and liposomal doxorubicin.

144 ved doxorubicin, epirubicin or non-pegylated liposomal-doxorubicin (10 mg/kg) and cardiac function wa

145 (PegIntron and Pegasys), and nanoparticles (Liposomal-Doxorubicin and quantum-dots).

146 In HL-1 cells, non-pegylated liposomal-doxorubicin generated significantly less react

147 nistering Pluronic block copolymers once the liposomal drug accumulates in the tumor sites.

148 e MALDI-IMS to analyze drug penetration of a liposomal drug carrier as well as its metabolites.

149 bility to both small dye molecules and large liposomal drug carriers were quantified using fluorescen

150 Advancements in liposomal drug delivery have produced long circulating a

151 rstanding is required to optimize and design liposomal drug delivery systems capable of controllable

152 Nanomedicine, particularly liposomal drug delivery, has expanded considerably over

153 se to identify novel candidate molecules for liposomal drug delivery.

154 ical activities, may be the basis for future liposomal drug development.

155 hysical marker of extravasation potential of liposomal drug formulations.

156 y, by supplementing ablation with concurrent liposomal drug therapy, a complete and durable response

157 er does not guarantee enhanced efficacy of a liposomal drug.

158 rably over the past few decades, and several liposomal drugs are already providing improved clinical

159 lly modulate the release and cytotoxicity of liposomal drugs in a delicate and predictable manner.

160 inical and commercial success of a number of liposomal drugs, each of which required a tailored formu

161 dels for the computer-model-driven design of liposomal drugs.

162 atechin or free green tea extract (GTE), and liposomal encapsulated catechin or liposomal encapsulate

163 GTE), and liposomal encapsulated catechin or liposomal encapsulated GTE.

164 rtezomib was not active against dKI AML, yet liposomal-encapsulated bortezomib, as a single agent, re

165 We measured liposomal encapsulation and cellular uptake of the monod

166 Overall, our work shows how liposomal encapsulation of irinotecan can safely improve

167 apsulation method to nucleobase analogues, a liposomal entrapment method once conceived useful only f

168 The entrapment efficiency of optimized liposomal fasudil formulations was between 68.1+/-0.8% a

169 shed the proof-of-principle that aerosolized liposomal fasudil is a feasible option for a non-invasiv

170 terminal plasma half-life was observed when liposomal fasudil was administered as aerosols.

171 One h after intratracheal instillation of liposomal fasudil, mean pulmonary arterial pressure (MPA

172 The current signal produced by the released liposomal Fe(CN)6(4-), measured using square wave voltam

173 ally confirmed using reconstituted MscL in a liposomal fluorescent efflux assay.

174 Doxorubicin (Dox) is approved for use in liposomal form for the treatment of ovarian cancer.

175 mers administered in soluble or high-density liposomal formats.

176 This nanoscale liposomal formulation (NLF) contains the pentapeptide mi

177 at the passive delivery of an edge-activated liposomal formulation can effectively carry siRNA throug

178 Topical liposomal formulation of cyclosporine, 2.0% w/w, is effe

179 CPX-351 is a liposomal formulation of cytarabine:daunorubicin designe

180 Doxil, a liposomal formulation of the chemotherapeutic drug doxor

181 of these specific macrophages, we designed a liposomal formulation of vancomycin that is efficiently

182 Liposomal formulation prevents undesirable side effects

183 TPT may benefit from liposomal formulation using active loading strategies to

184 the circulation after the administration of liposomal formulation was characterized by prolonged cir

185 The optimized diaCEST liposomal formulation with a BA-to-lipid ratio of 25% ex

186 did not show any efficacy advantage for the liposomal formulation.

187 to monitor TPT release from actively loaded liposomal formulations having a low intravesicular pH.

188 ns, with the largest class of products being liposomal formulations intended for cancer treatments.

189 Temperature-sensitive liposomal formulations of chemotherapeutics, such as dox

190 a variety of lipid components may be used in liposomal formulations of GLA.

191 Liposomal formulations of N-BP have been proposed to imp

192 ty and performance seen with actively-loaded liposomal formulations of TPT and other weakly-basic ant

193 Liposomal formulations of VE analogues especially of alp

194 Present achievements in: (i) preparation of liposomal formulations of VE analogues, (ii) physico-che

195 d to decrease for about 3 h, suggesting that liposomal formulations produced pulmonary preferential v

196 ture and the imminent arrival of theranostic liposomal formulations to move this field forward.

197 Resulting liposomal formulations were found to preserve the origin

198 Various liposomal formulations were tested: conventional liposom

199 enicity in both free (micellar) state and in liposomal formulations when tested in rabbits in vivo (s

200 ty and physicochemical properties typical of liposomal formulations, preferentially targeted inflamed

201 Through comparisons to liposomal formulations, which have been studied extensiv

202 ling during UF; and (3) preozonation reduces liposomal fouling during UF, likely due to the disruptio

203 We hypothesize that liposomal fusion of 15-epi-LXA4 (Lipo-15-epi-LXA4) or fr

204 d for ATP-mediated drug release triggered by liposomal fusion.

205 The trans-placental permeability of liposomal Gadolinium (Gd) nanoparticle contrast agents w

206 re summarize the progress made in the use of liposomal GC formulations for the treatment of asthma, r

207 ectably low transplacental permeation of the liposomal Gd agent, while the clinical agent (Multihance

208 enate dimeglumine), and a novel experimental liposomal Gd agent.

209 determine both maternal and fetal safety of liposomal Gd is suggested.

210 creased tumor uptake of both gemcitabine and liposomal gemcitabine and significantly improved anti-tu

211 ignificantly improved anti-tumor efficacy of liposomal gemcitabine.

212 Our data thus demonstrate that liposomal gp41 MPER formulation can induce neutralizatio

213 ation in dLNs compared with a combination of liposomal HIV gp41 and soluble CDN.

214 A combination of a poorly immunogenic liposomal HIV gp41 peptide antigen and NP-cdGMP robustly

215 ed membrane permeabilization is enabled with liposomal inclusion of 10 molar % porphyrin-phospholipid

216 Liposomal-iodine formulations varying in particle size a

217 rophage-rich atherosclerotic plaques using a liposomal-iodine nanoparticle contrast agent and dual-en

218 e plaques, we evaluated the feasibility of a liposomal-iodine nanoparticle contrast agent for compute

219 able, focusing on this new generation of non-liposomal L-NVs and showing their similarities and diffe

220 field of L-NV design and synthesis, and non-liposomal L-NVs have been recently developed; this new g

221 tigated the in vivo therapeutic potential of liposomal linolenic acid (LipoLLA) for the treatment of

222 old nanoparticles that are encapsulated in a liposomal (Lip) system that can produce H2 gas in situ u

223 are taken up, their CE core is hydrolyzed by liposomal lipases to generate free cholesterol (FC).

224 This conjugate was incorporated into the liposomal lipid bilayer, and the modified liposomes were

225 dithiol (1KDa), a free radical initiator and liposomal lipids at the liposome formation step.

226 irradiation at 730 nm led to peroxidation of liposomal lipids, allowing drug release.

227 duced by mechanically induced defects in the liposomal membrane caused by the oscillation of the iron

228 cell-penetrating peptide-modified fusogenic liposomal membrane was coated on the core, which had an

229 However, when the phospholipids within the liposomal membrane were hydrolyzed by PLA2, encapsulated

230 coil forming lipidated peptides embedded in liposomal membranes are able to induce rapid, controlled

231 -10 nor the heterodimer, interacted with the liposomal membranes at acidic conditions, which was evid

232 The interaction of liposomal membranes composed of soybean phosphatidylchol

233 correct insertion of lipidated peptides into liposomal membranes, a small library of lipidated coiled

234 ed Bcl2 interacting protein) in assays using liposomal membranes.

235 de anion and sodium cation transport in both liposomal models and cells, and promote cell death by in

236 enhance the transport of chloride anions in liposomal models and promote sodium chloride influx into

237 long PEG chains was investigated using three liposomal models.

238 ely and support the rapid translation of new liposomal nanomedicines from bench to bedside, new cost-

239 s for decades, resulting in several approved liposomal nanomedicines used in the clinic.

240 e formulated into a core-membrane structured liposomal nanoparticle (NP).

241 It is a liposomal nanoparticle loaded with a synthetic mimic of

242 , recent reports show that certain pegylated liposomal nanoparticles (PLNs) and polymeric nanoparticl

243 Liposomal nanoparticles are the most commonly used drug

244 combination with a near-infrared dye, these liposomal nanoparticles can serve as bimodal PET/optical

245 We find that liposomal nanoparticles decorated with Ag and Siglec-G l

246 evelop an (89)Zr-based labeling strategy for liposomal nanoparticles that accumulate in tumors via pa

247 e natural ligand and is capable of targeting liposomal nanoparticles to Sn-expressing cells in vivo.

248 strates the incorporation of bortezomib into liposomal nanoparticles via reversible boronic ester bon

249 r and efficient strategy for the labeling of liposomal nanoparticles with (89)Zr.

250 Here we show that liposomal nanoparticles, displaying both antigen and gly

251 delivered to human CD1b(+) DCs via targeted liposomal nanoparticles, leading to robust group 1 CD1-r

252 f liposomes to yield stable and reproducible liposomal nanoparticles.

253 opment of a novel tumor vasculature-targeted liposomal nanoprobe by conjugating a human monoclonal an

254 The liposomal nanoprobe PGN-L-IO/DiR was fully characterized

255 g were performed after i.v. injection of the liposomal nanoprobes into mice bearing breast MDA-MB231

256 bead-based immunoassay platform, composed of liposomal nanovesicle amplification system, Gentamycin s

257 The mean particle size of liposomal nanovesicles containing PF30 was found to be i

258 Fluorescent dye-loaded protein G-liposomal nanovesicles were then added to specifically b

259 eased by adding a detergent solution to lyse liposomal nanovesicles.

260 , interacts reversibly and peripherally with liposomal NPs without experiencing significant structura

261 emained limited due to the slow diffusion of liposomal particles within the tumor and limited release

262 , (ii) development of PEGylated and targeted liposomal PAs, (iii) physico-chemical characterization o

263 review analyzes these techniques applied to liposomal, PEI, dendrimer, stem cell and viral gene deli

264 C-3 cell line, and binding was observed with liposomal peptide concentrations as low as 0.16mol%.

265 ntaining luciferase reporter gene) to form a liposomal-plasmid DNA (LpDNA) complex.

266 After that, spray dried liposomal powders containing BME were added to chocolate

267 ared to spray dried extract, chitosan coated liposomal powders provided better protection of anthocya

268 om magic angle spinning solid-state NMR of a liposomal preparation strongly support the quaternary st

269 The co-loaded liposomal preparation was also targeted to the transferr

270 A novel liposomal preparation was developed, co-loaded with NCL-

271 hysical stability and oxidative stability of liposomal PUFAs increased as the size of the liposomes d

272 fluorescence method was developed to monitor liposomal release kinetics of the anticancer agent topot

273 ese findings, the developed model describing liposomal release of TPT may be used in the future to ev

274 Atu027 is a novel liposomal RNA interference therapeutic that includes a s

275 nt study, an electrochemical method based on liposomal signal amplification platform is proposed for

276 t inhibition of angiopoietin-2 expression by liposomal siRNA in vivo improved absolute survival by 50

277 ng promotes the delivery and transfection of liposomal siRNA.

278 This composition was shown to increase liposomal stability, prolong the circulation half-life,

279 Vesosomes are nested liposomal structures with high potential as advanced dru

280 erest for stabilization/functionalization of liposomal surfaces as well as detection of polyvalent mo

281 replacement by intra-articular injection of liposomal suspensions containing adenosine prevents deve

282 An efficient liposomal system for screening the zinc ionophore activi

283 echanism was explicitly demonstrated using a liposomal system that recapitulates BAK-mediated release

284 transmembrane proteins reconstituted into a liposomal system.

285 ed to investigate the antifungal activity of liposomal systems containing Spirulina sp. LEB-18 phenol

286 vitro findings, we utilized a novel anginex/liposomal targeting of murine angiogenic endothelium wit

287 The features of this ultra-sensitive liposomal TIRF-FOB are (i) fluorescence is excited via e

288 d optimize loading and subsequent release of liposomal TPT formulations utilizing active loading stra

289 n against Cu(2+)-mediated degradation of the liposomal unsaturated fatty acids).

290 PEGylated liposomes with pHLIP might affect liposomal uptake by cells.

291 However, liposomal uptake was significantly correlated with tumor

292 ns could be made regarding the EPR effect or liposomal uptake.

293 the immunostimulatory effect of the cationic liposomal vaccine adjuvant dimethyldioctadecylammonium a

294 Liposomal vaccine formulations incorporating stimulants

295 The anti-cancer effect of these liposomal VE analogues has been successfully demonstrate

296 ovel bi-ligand (transferrin-poly-l-arginine) liposomal vector for delivery of desired gene to brain,

297 ing with enhanced cell penetration to design liposomal vectors for improving the transport of molecul

298 udil (HA-1077), a Rho-kinase inhibitor, into liposomal vesicles results in prolonged vasodilation in

299 Liposomal vincristine is also approved for relapsed dise

300 been suggested as a suitable alternative to liposomal ZOL (L-ZOL), due to unexpected mice death expe

301 However, liposomal zoledronic acid proved highly toxic to SCID Be